bosentan anhydrous has been researched along with Behcet Syndrome in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Daele, PLAV; Dik, WAV; Hagen, PMV; Houwen, TBV; Kappen, JH; Kuijpers, RWAM; Laar, JAMV | 1 |
1 trial(s) available for bosentan anhydrous and Behcet Syndrome
Article | Year |
---|---|
A pilot study into bosentan (Tracleer®) as an immunomodulating agent in patients with Behçet's disease.
Topics: Behcet Syndrome; Bosentan; Cytokines; Endothelial Cells; Humans; Pilot Projects; Prospective Studies | 2022 |